Buprenorphine in the treatment of non-suicidal self-injury: a case series and discussion of the literature

References

1. Jacobson CM, Gould M. The epidemiology and phenomenology of non-suicidal self-injurious behavior among adolescents: a critical review of the literature. Arch Suicide Res 2007;11:129–47.10.1080/13811110701247602Suche in Google Scholar PubMed

2. Sinclair J, Gray A, Rivero-Arias O, Saunders K, Hawton K. Healthcare and social services resource use and costs of self-harm patients. Soc Psychiatr Psychiatric Epidemiol 2011;46:263–71.10.1007/s00127-010-0183-5Suche in Google Scholar PubMed

3. Whitlock J, Knox KL. The relationship between self-injurious behavior and suicide in a young adult population. Arch Pediatr Adolesc Med 2007;161:634–40.10.1001/archpedi.161.7.634Suche in Google Scholar PubMed

4. Glenn CR, Klonsky ED. Prospective prediction of nonsuicidal self-injury: a 1-year longitudinal study in young adults. Behav Ther 2011;42:751–62.10.1016/j.beth.2011.04.005Suche in Google Scholar PubMed PubMed Central

5. Hawton K, Fagg J. Suicide, and other causes of death, following attempted suicide. Br J Psychiatry 1988;152:359–66.10.1192/bjp.152.3.359Suche in Google Scholar PubMed

6. Herpertz S. Self-injurious behaviour. Psychopathological and nosological characteristics in subtypes of self-injurers. Acta Psychiatr Scand 1995;91:57–68.10.1111/j.1600-0447.1995.tb09743.xSuche in Google Scholar PubMed

7. Zlotnick C, Mattia JI, Zimmerman M. Clinical correlates of self-mutilation in a sample of general psychiatric patients. J Nerv Ment Dis 1999;187:296–301.10.1097/00005053-199905000-00005Suche in Google Scholar PubMed

8. Briere J, Gil E. Self-mutilation in clinical and general population samples: prevalence, correlates, and functions. Am J Orthopsychiatry 1998;68:609–20.10.1037/h0080369Suche in Google Scholar PubMed

9. Klonsky ED, Oltmanns TF, Turkheimer E. Deliberate self-harm in a nonclinical population: prevalence and psychological correlates. Am J Psychiatry 2003;160:1501–8.10.1176/appi.ajp.160.8.1501Suche in Google Scholar PubMed PubMed Central

10. Norelli LJ, Coates AD, Kovasznay BK. Cancer risk from diagnostic radiology in a deliberate self-harm patient. Acta Psychiatr Scand 2010;122:427–30.10.1111/j.1600-0447.2010.01538.xSuche in Google Scholar PubMed

11. Selby EA, Bender TW, Gordon KH, Nock MK, Joiner TE Jr. Non-suicidal self-injury (NSSI) disorder: a preliminary study. Personal Disord 2012;3:167–75.10.1037/a0024405Suche in Google Scholar PubMed

12. Nonsuicidal self-injury. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Publishing, 2013: 783–808.Suche in Google Scholar

13. Moscicki EK, O Carroll P, Rae DS, Locke BZ, Roy A, et al. Suicide attempts in the Epidemiologic Catchment Area Study. Yale J Biol Med 1988;61:259–68.Suche in Google Scholar

14. Schmidtke A, Bille-Brahe U, De Leo D, Kerkhof A, Bjerke T, et al. Attempted suicide Europe: rates, trends, and sociodemographic characteristics of suicide attempters during the period 1989–1992. Results of the WHO/EURO Multicentre Study on Parasuicide. Acta Psychiatr Scand 1996;93:327–38.10.1111/j.1600-0447.1996.tb10656.xSuche in Google Scholar PubMed

15. Nock MK, Joiner TE, Gordon KH, Lloyd-Richardson E, Prinstein MJ. Non-suicidal self-injury among adolescents: diagnostic correlates and relation to suicide attempts. Psychol Res 2006;144:65–72.10.1016/j.psychres.2006.05.010Suche in Google Scholar PubMed

16. Sher L, Stanley BH. The role of endogenous opioids in the pathophysiology of self-injurious and suicidal behavior. Arch Suicide Res 2008;12:299–308.10.1080/13811110802324748Suche in Google Scholar PubMed

17. Prossin AR, Love TM, Koeppe RA, Zubeita J, Silk KR. Dysregulation of regional endogenous opioid function in borderline personality disorder. Am J Psychiatry 2010;167:925–33.10.1176/appi.ajp.2010.09091348Suche in Google Scholar PubMed PubMed Central

18. Kennedy SE, Koeppe RA, Young EA, Zubeita J. Dysregulation of opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006;63:1199–208.10.1001/archpsyc.63.11.1199Suche in Google Scholar PubMed

19. Mercer D. Medications in the treatment of borderline personality disorder 2006. Curr Psychiatry Rep 2007;9:53–62.10.1007/s11920-007-0010-1Suche in Google Scholar PubMed

20. Bystritsky A, Strausser BP. Treatment of obsessive-compulsive cutting behavior with naltrexone. J Clin Psychiatry 1996;57:423–4.Suche in Google Scholar

21. McGee MD. Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. J Clin Psychiatry 1997;58:32–3.10.4088/JCP.v58n0106eSuche in Google Scholar

22. Agarwal LJ, Berger CE, Gill L. Naltrexone for severe self-harm behavior: a case report. Am J Psychiatry 2011;168:437–8.10.1176/appi.ajp.2010.10101493Suche in Google Scholar PubMed

23. Roth AS, Ostroff RB, Hoffman RE. Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. J Clin Psychiatry 1996;57:233–7.Suche in Google Scholar

24. Kahan M, Srivastava A, Ordean A, Cirone S. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician 2011;57:281–9.Suche in Google Scholar

25. Tzschentke TM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berl) 2002;161:1–16.10.1007/s00213-002-1003-8Suche in Google Scholar PubMed

26. Ide S, Minami M, Satoh M, Uhl GR, Sora I, et al. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in μ-opioid receptor knockout mice. Neuropsychopharmacology 2004;29:1656–63.10.1038/sj.npp.1300463Suche in Google Scholar

27. Robinson SE. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev 2002;8:377–90.10.1111/j.1527-3458.2002.tb00235.xSuche in Google Scholar

28. Wnendt S, Krüger T, Janocha E, Hildebrandt D, Englberger W. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered gene assay. Mol Pharmacol 1999;56:334–8.10.1124/mol.56.2.334Suche in Google Scholar

29. Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 2000;21:1141–6.10.1016/S0196-9781(00)00252-7Suche in Google Scholar

30. Leander DJ. Opioid agonist and antagonist behavioral effects of buprenorphine. Br J Pharmacol 1983;78:607–15.10.1111/j.1476-5381.1983.tb09410.xSuche in Google Scholar

31. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid-dependent humans. J Pharmacol Exp Ther 1988;247:47–53.Suche in Google Scholar

32. Walker EA, Zernig G, Woods JH. Buprenorphine antagonism of μ opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther 1995;273:1345–52.Suche in Google Scholar

33. Woods JH, France CP, Winger GD. Behavioral pharmacology of buprenorphine: issues relevant to its potential in treating abuse. NIDA Res Monogr 1992;121:12–27.Suche in Google Scholar

34. Cowan A, Lewis JW, MacFarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977;60:537–45.10.1111/j.1476-5381.1977.tb07532.xSuche in Google Scholar

35. Dum JE, Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 1981;74:627–33.10.1111/j.1476-5381.1981.tb10473.xSuche in Google Scholar

36. Villiger J, Taylor K. Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Sci 1981;29: 2699–708.10.1016/0024-3205(81)90529-4Suche in Google Scholar

37. Boas R, Villiger J. Clinical actions of fentanyl and buprenorphine. Br J Anaesth 1985;57:192–6.10.1093/bja/57.2.192Suche in Google Scholar

38. Rance MJ, Dickens JM. The influence of drug-receptor kinetics on the pharmacological and pharmacokinetic profiles of buprenorphine. In: Van Ree J, Terenius L, editors. Characteristics and functions of opioids. Amsterdam: Elsevier, 1978:65–6.Suche in Google Scholar

39. Mello NK, Bree MP, Mendelson JH. Buprenorphine self administration by rhesus monkeys. Pharmacol Biochem Behav 1981;15:215–25.10.1016/0091-3057(81)90180-5Suche in Google Scholar

40. Dykstra LA. Behavioral effects of buprenorphine and diprenorphine under a multiple schedule of food presentation in squirrel monkeys. J Pharmacol Exp Ther 1983;226:317–23.Suche in Google Scholar

41. France CP, Jacobson AE, Woods JH. Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine. J Pharmacol Exp Ther 1984;230:652–7.Suche in Google Scholar

42. France CP, Woods JH. Opiate agonist-antagonist interactions: application of a three-key drug discrimination procedure. J Pharmacol Exp Ther 1985;234:81–9.Suche in Google Scholar

43. Young AM, Kapitsopoulos G, Makhay MM. Tolerance to morphine-like stimulus effects of μ opioid agonists. J Pharmacol Exp Ther 1991;257:795–805.Suche in Google Scholar

44. Brandt MR, Cabansag SR, France CP. Discriminative stimulus effects of 1-α-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 1997;282:574–84.Suche in Google Scholar

45. Briscoe RJ, Winger G, Lewis JW, Woods JH. Methoclocinnamox: time course of changes in alfentanil reinforced responding in rhesus monkeys. Psychopharmacology 2000;148:393–9.10.1007/s002130050068Suche in Google Scholar PubMed

46. Mogil JS, Wilson SG, Chesler EJ, Rankin AL, Nemmani KV, et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA 2003;100:4867–72.10.1073/pnas.0730053100Suche in Google Scholar PubMed PubMed Central

47. Steiner H, Gerfen CR. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res 1998;123:60–76.10.1007/s002210050545Suche in Google Scholar PubMed